269 related articles for article (PubMed ID: 35857294)
1. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
Tabrizian P; Holzner ML; Mehta N; Halazun K; Agopian VG; Yao F; Busuttil RW; Roberts J; Emond JC; Samstein B; Brown RS; Najjar M; Chapman WC; Doyle MM; Florman SS; Schwartz ME; Llovet JM
JAMA Surg; 2022 Sep; 157(9):779-788. PubMed ID: 35857294
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
3. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis.
Barakat O; Wood RP; Ozaki CF; Ankoma-Sey V; Galati J; Skolkin M; Toombs B; Round M; Moore W; Mieles L
Liver Transpl; 2010 Mar; 16(3):289-99. PubMed ID: 20209588
[TBL] [Abstract][Full Text] [Related]
4. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
5. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G
JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167
[TBL] [Abstract][Full Text] [Related]
6. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
7. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Successful Downstaging of Hepatocellular Carcinoma Outside Milan Criteria.
Murali AR; Romero-Marrero C; Miller C; Aucejo F; Levitin A; Gill A; McLennan G; Karuppasamy K; Zein NN; Lopez R; Menon KV
Transplantation; 2016 Nov; 100(11):2391-2397. PubMed ID: 27780187
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
[TBL] [Abstract][Full Text] [Related]
10. Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: A multicenter study from China.
Zhan QF; Ling SB; Deng YN; Shan QN; Ye QW; Xu SJ; Jiang GJ; Lu D; Wei XY; Zhuang L; Zhang W; Shen T; Cen BN; Xie HY; Liu JM; Wu J; Zheng SS; Yang Y; Xu X
Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):349-357. PubMed ID: 32622826
[TBL] [Abstract][Full Text] [Related]
11. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
[TBL] [Abstract][Full Text] [Related]
12. Liver transplantation in hepatocellular carcinoma - should we perform downstaging?
Filipec Kanižaj T; Dinjar Kujundžić P; Ostojić A; Mijić M; Sertić Milić H; Mijić A; Mateljak M; Martinčević D; Radetić E; Vidjak V; Kocman B; Mikolašević I
Croat Med J; 2022 Aug; 63(4):317-325. PubMed ID: 36046928
[TBL] [Abstract][Full Text] [Related]
13. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
14. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
15. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions.
Chapman WC; Garcia-Aroz S; Vachharajani N; Fowler K; Saad N; Lin Y; Wellen J; Tan B; Khan AS; Doyle MB
J Am Coll Surg; 2017 Apr; 224(4):610-621. PubMed ID: 28069527
[TBL] [Abstract][Full Text] [Related]
16. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.
Lei JY; Yan LN; Wang WT
World J Gastroenterol; 2013 Jul; 19(27):4400-8. PubMed ID: 23885153
[TBL] [Abstract][Full Text] [Related]
17. Benefit of downsizing hepatocellular carcinoma in a liver transplant population.
Jang JW; You CR; Kim CW; Bae SH; Yoon SK; Yoo YK; Kim DG; Choi JY
Aliment Pharmacol Ther; 2010 Feb; 31(3):415-23. PubMed ID: 19821808
[TBL] [Abstract][Full Text] [Related]
18. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
19. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation.
Sharr WW; Chan SC; Lo CM
Transplantation; 2014 Apr; 97 Suppl 8():S10-7. PubMed ID: 24849822
[TBL] [Abstract][Full Text] [Related]
20. Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence - a retrospective study.
Toso C; Meeberg G; Andres A; Shore C; Saunders C; Bigam DL; Shapiro AMJ; Compagnon P; Berney T; Majno P; Kneteman N
Transpl Int; 2019 Feb; 32(2):163-172. PubMed ID: 30152891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
